



**Prof. RNDr. Jaroslav Turánek, DSc.**

**Head of Research and Development at C2P NEXARS**

He has more than 30 years' experience in bionanotechnology and immunopharmacology focused on drug delivery systems based on liposomes, construction of self-assembled vaccination nanoparticles and molecular-based adjuvants. He is pioneering the technologies of nanofibre-based mucoadhesive films for non-invasive mucosal vaccination and "printed vaccine technology". He has completed his PhD at the age of 27 years from Masaryk University Brno. He founded the Department of Pharmacology and Immunotherapy at Veterinary Research Institute, Brno. He has published in prestigious impacted scientific journals more than 100 papers, 9 patents and 7 book chapters on vaccines, drug targeting, anticancer and antimicrobial drugs. He is teaching immunology, biotechnology and immunochemistry at Masaryk University Brno and Technical University Brno. He is the founding member and president of Czech Society for Gene and Cell Therapy. He prepared and led several multidisciplinary complex projects within OP VVV and OP VK calls focused on application of nanotechnology and biotechnology approach for development of new modern vaccines and targeted drug delivery systems, as well as new education projects.

His excellent research results (publications, patents) were presented in the media, highly appreciated by the Czech society and together with his colleagues he was nominated for prestigious award Česká hlava (Czech Head 2014 and 2018). Technology Agency of the Czech Republic and American Chamber of Commerce in the Czech Republic awarded him in 2014 and 2015 for the best collaboration with Industry and for the best project in the field of public health, respectively.